NeuroPace (Nasdaq:NPCE) announced that Michael Favet resigned from his position as CEO and as a member of the company’s board of directors. Favet’s resignation goes into effect on July 10, 2023. He intends to participate in NeuroPace’s officer severance benefit plan, according to a news release. The company — maker of the FDA-approved RNS system […]
NeuroPace
NeuroPace announces first patient implant in trial of neuromod treatment for epilepsy
NeuroPace (Nasdaq:NPCE) announced that the first patient received their implant in the Nautilus clinical study of its RNS system. The company’s Nautilus study evaluates the safety and efficacy of its RNS system. It aims to treat individuals aged 12 and older with drug-resistant idiopathic generalized epilepsy (IGE). This is also known as primary generalized epilepsy. […]
MedTech 100 roundup: New all-time best reached
Once again, the medtech industry has soared to new heights, eclipsing its all-time best performance by the tiniest of margins. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (July 2) at 114.59 points. It was just 0.01 points ahead of the 114.58-point mark set in […]
NeuroPace wins five-year $9.3M grant from NIH
NeuroPace today announced that it has received a $9.3 million National Institutes of Health grant to study Lennox-Gastaut Syndrome treatment. The NIH — through the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative — will provide up to $9.3 million over a five-year period to evaluate the use of Mountain View, Calif.-based NeuroPace’s RNS neuromodulation […]
MedTech 100 roundup: New heights reached again
One week after recording its all-time best performance, the medtech industry again topped itself, storming even further ahead. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has been on the rise since April began, with last week’s mark of 112.25 (April 16) representing an all-time best, topping the […]
DeviceTalks Weekly Podcast – iRhythm CEO Mike Coyle, New Podcast!
In this podcast, iRhythm CEO Mike Coyle discusses his decision to join the digital health leader in January. Coyle’s had to hit the ground running as iRhythm manages some challenging decisions from regional Medicare payors, but he also sees great opportunity for the company’s Zio platform across the healthcare spectrum. In this conversation, Coyle discusses […]
NeuroPace shares take off on first day of trading
Epilepsy treatment developer NeuroPace (NSDQ:NPCE) shares skyrocketed today during its first day of trading on the Nasdaq market. Mountain View, Calif.-based NeuroPace shares were trading up 37.4% at $23.35 per share in mid-afternoon trading today. The company announced last month that it filed with the SEC to raise up to $75 million in an initial […]
MedTech 100 roundup: Heading back to previous heights?
Although March brought on tough times for top stocks in the medtech industry, April is already showing signs of a rebound. The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest […]
NeuroPace files for $75M IPO
Refractory focal epilepsy treatment developer NeuroPace last week filed with the SEC to raise up to $75 million in an initial public offering. Mountain View, Calif-based NeuroPace develops the RNS system, which it touts as the world’s only closed-loop brain-responsive neurostimulation system designed to prevent seizures at their source. The RNS system includes a neurostimulator, […]
DTW Podcast: KCK’s Long says deals getting done during COVID era
In this week’s DeviceTalks Weekly Podcast, Karen Long, managing director at KCK Group, says startups looking for funding have an opportunity to catch the eye and ear of investors. KCK, an active medtech investor, has been involved in two sizable investments this summer including Aerin Medical and NeuroPace. Both were portfolio companies, but Long says […]
NeuroPace raises $67M for RNS system
NeuroPace announced today that it raised $67 million for its RNS system for treating refractory focal epilepsy. Accelmed Partners led the round, while an unnamed strategic investor, Revelation Partners, Soleus Capital and returning investors KCK Group and OrbiMed Advisors also participated, according to a news release. Mountain View, Calif-based NeuroPace’s financing includes $33 million in […]
